Creative Planning grew its holdings in Luminex Co. (NASDAQ:LMNX) by 4.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 12,507 shares of the medical instruments supplier’s stock after buying an additional 501 shares during the quarter. Creative Planning’s holdings in Luminex were worth $290,000 as of its most recent filing with the SEC.
Several other hedge funds have also made changes to their positions in the company. Everence Capital Management Inc. acquired a new position in shares of Luminex in the 4th quarter valued at $220,000. California Public Employees Retirement System raised its stake in shares of Luminex by 170.2% in the 4th quarter. California Public Employees Retirement System now owns 210,132 shares of the medical instruments supplier’s stock valued at $4,867,000 after buying an additional 132,358 shares in the last quarter. Dupont Capital Management Corp acquired a new position in shares of Luminex in the 4th quarter valued at $1,521,000. Campbell & CO Investment Adviser LLC acquired a new position in shares of Luminex in the 4th quarter valued at $329,000. Finally, Gibson Capital LLC acquired a new position in shares of Luminex in the 4th quarter valued at $477,000. Institutional investors own 80.85% of the company’s stock.
A number of equities analysts have recently issued reports on LMNX shares. BTIG Research dropped their price objective on shares of Luminex to $32.00 and set a “buy” rating for the company in a research note on Monday, November 11th. BidaskClub upgraded shares of Luminex from a “hold” rating to a “buy” rating in a research report on Tuesday, February 4th. Finally, ValuEngine cut shares of Luminex from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 3rd. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $23.33.
In related news, Director G Walter Loewenbaum II purchased 2,955 shares of the business’s stock in a transaction on Monday, November 18th. The shares were purchased at an average price of $19.80 per share, with a total value of $58,509.00. Following the completion of the purchase, the director now owns 584,551 shares in the company, valued at approximately $11,574,109.80. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 8.70% of the company’s stock.
LMNX opened at $24.03 on Friday. The company has a current ratio of 3.52, a quick ratio of 2.17 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $1.09 billion, a PE ratio of -267.00 and a beta of 0.83. Luminex Co. has a 1-year low of $17.34 and a 1-year high of $26.82. The firm has a 50-day moving average price of $23.21 and a two-hundred day moving average price of $21.39.
Luminex (NASDAQ:LMNX) last posted its quarterly earnings data on Monday, February 10th. The medical instruments supplier reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.08. The firm had revenue of $90.50 million during the quarter, compared to analysts’ expectations of $90.27 million. Luminex had a negative net margin of 1.18% and a negative return on equity of 2.03%. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.04 EPS. On average, research analysts predict that Luminex Co. will post 0.1 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Thursday, December 19th were paid a dividend of $0.09 per share. This represents a $0.36 annualized dividend and a yield of 1.50%. The ex-dividend date was Wednesday, December 18th. Luminex’s payout ratio is -171.43%.
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market.
Recommended Story: How much money do you need to begin day trading?
Want to see what other hedge funds are holding LMNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Luminex Co. (NASDAQ:LMNX).
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.